Revenue Performance - Total revenue for the full year 2024 decreased by 5% to 17.4millionfrom18.2 million in 2023[5] - Recurring revenue for the full year 2024 increased by 9% to 12.0millioncomparedto11.0 million in 2023[5] - Fourth quarter 2024 revenue increased by 10% year-over-year to 4.8millioncomparedto4.4 million in Q4 2023[5] - Total recurring revenue for Q4 2024 was 3,296thousand,down10.33,675 thousand in Q4 2023[31] - Total revenue for Q4 2024 increased to 4,797thousand,comparedto4,374 thousand in Q4 2023, representing an increase of 9.6%[31] - Total revenue for the twelve months ended December 31, 2024 was 17,389thousand,adecreaseof4.718,244 thousand in 2023[31] Profitability and Loss - Net loss for the full year 2024 improved by 39% to 4.4millionfrom7.3 million in 2023[5] - Fourth quarter 2024 net loss decreased by 72% year-over-year to 1.2millioncomparedto4.2 million in Q4 2023[5] - The net loss for Q4 2024 was (1,192)thousand,animprovementfrom(4,238) thousand in Q4 2023[29] - Adjusted EBITDA loss for the full year 2024 improved by 15% to 3.9millioncomparedto4.6 million in 2023[5] - Adjusted EBITDA for Q4 2024 was (829)thousand,animprovementfrom(1,218) thousand in Q4 2023[29] - Adjusted EBITDA loss for the fourth quarter 2024 improved by 32% to 0.8millioncomparedto1.2 million in Q4 2023[10] Cash and Securities - Cash and cash equivalents and marketable securities totaled 27.8millionattheendof2024,downfrom30.9 million at the end of 2023[13] Share Repurchase - The company repurchased 137,051 shares at a cost of 0.2millionduringtheyear[5]StrategicFocus−Awareisfocusingonstrengtheningkeypartnershipsandacceleratingtechnologyadvancementstocapitalizeontheexpandingmarketopportunityinbiometricsecurity[7]Stock−BasedCompensation−Stock−basedcompensationforthetwelvemonthsendedDecember31,2024was1,132 thousand, down 25.7% from $1,525 thousand in 2023[29] Future Expectations - The company expects to continue incurring expenses similar to those reflected in the adjusted EBITDA calculations[27]
